CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Clopidogrel 75mgWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (7)


Name (Synonyms) Correlation
drug1824 Placebo (PBO) Wiki 1.00
drug239 Atorvastatin 40mg Wiki 1.00
drug35 300 mg EIDD-2801 Wiki 1.00
drug2106 Rivaroxaban 2.5 MG Wiki 1.00
drug1679 Omeprazole 20mg Wiki 1.00
drug219 Aspirin 75mg Wiki 1.00
drug24 200 mg EIDD-2801 Wiki 0.71

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D054058 Acute Coronary Syndrome NIH 0.58

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.

The outbreak of a novel coronavirus (SARS-CoV-2) and associated COVID-19 disease in late December 2019 has led to a global pandemic. At the time of writing, there have been 150 000 confirmed cases and 3500 deaths. Apart from the morbidity and mortality directly related to COVID-19 cases, society has had to also cope with complex political and economic repercussions of this disease. At present, and despite pressing need for therapeutic intervention, management of patients with COVID-19 is entirely supportive. Despite the majority of patients experiencing a mild respiratory illness a subgroup, and in particular those with pre-existing cardiovascular disease, will experience severe illness that requires invasive cardiorespiratory support in the intensive care unit. Furthermore, the severity of COVID-19 disease (as well as the likelihood of progressing to severe disease) appears to be in part driven by direct injury to the cardiovascular system. Analysis of data from two recent studies confirms a significantly higher likelihood of acute cardiac injury in patients who have to be admitted to intensive care for the management of COVID-19 disease. The exact type of acute of cardiac injury that COVID-19 patients suffer remains unclear. There is however mounting evidence that heart attack like events are responsible. Tests ordinarily performed to definitely assess for heart attacks will not be possible in very sick COVID-19 patients. Randomising patients to cardioprotective medicines will help us understand the role of the cardiovascular system in COVID-19 disease. It will also help us determine if there is more we can do to treat these patients.

NCT04333407 COVID-19 Drug: Aspirin 75mg Drug: Clopidogrel 75mg Drug: Rivaroxaban 2.5 MG Drug: Atorvastatin 40mg Drug: Omeprazole 20mg
MeSH:Acute Coronary Syndrome

Primary Outcomes

Description: All-cause mortality

Measure: All-cause mortality at 30 days after admission

Time: at 30 days after admission

Secondary Outcomes

Description: Absolute change in serum troponin from admission (or from suspicion/diagnosis of Covid-19 if already an inpatient) measurement to peak value (measured using high sensitivity troponin assay). (Phase I interim analysis)

Measure: Absolute change in serum troponin from admission to peak value

Time: within 7 days and within 30 days of admission

Description: Discharge Rate: Proportion of patients discharged (or documented as medically fit for discharge)

Measure: Discharge Rate

Time: at 7 days and 30 days after admission

Description: Intubation Rate: Proportion of patients who have been intubated for mechanical ventilation

Measure: Intubation Rate

Time: at 7 days and at 30 days after admission


No related HPO nodes (Using clinical trials)